Frequently Asked Questions
The FDA-cleared UroLift System is the only treatment that uses the Prostatic Urethral Lift (PUL) procedure. The UroLift System treatment is a proven, minimally invasive approach for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) that can get men off BPH medications and avoid major surgery. The UroLift System’s permanent implants, delivered during a minimally invasive outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.
As with any medical procedure, individual results may vary. Speak with your urologist to see if the UroLift System treatment is right for you. Most common side effects are mild to moderate and include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and/or the inability to control the urge. Most symptoms resolve within two to four weeks after the procedure.
The UroLift System consists of a delivery device and small permanent implants.
- The UroLift Delivery Device is placed through the obstructed urethra.
- Small UroLift Implants are placed to lift or hold the enlarged prostate tissue out of the way like a curtain-tie. The Implants are delivered through a small needle that comes out of the delivery device and into the prostate.
- The UroLift Delivery Device is removed, leaving an open urethra that provides symptom relief.
The UroLift System does not keep someone from having future BPH treatments if they are necessary.
The UroLift System
What to Expect
Non-clinical testing has demonstrated that the UroLift Implant is MR Conditional. A patient with this device can be safely scanned in an MR system immediately after placement meeting the following conditions:
- Static magnetic field of 3.0 Tesla or less
- Maximum spatial field gradient of 1,500 Gauss/cm (15 T/m) (extrapolated)
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 4 W/kg for 15 minutes of continuous scanning (i.e., per pulse sequence) (First Level Controlled Operating Mode)
Under the scan conditions defined above, the UroLift Implant is expected to produce a maximum temperature rise of 2.4°C after 15 minutes of continuous scanning (i.e., per pulse sequence)
In non-clinical testing, the image artifact caused by the device extends approximately 15 mm from the UroLift Implant when imaged with a gradient echo pulse sequence and a 3.0 Tesla MRI system.
The safety of the delivery system has not been evaluated in the MR environment, and therefore, the implant deploying device should not be used within the MR environment.
Patient implant cards are provided to inform the patient that the UroLift implant is MR Conditional and can safely be scanned only under specific MR conditions.
If you have any questions about MRI safety, please consult your doctor.
You can also download the printable version of our patient MRI card.
In our clinical studies, the most common side effects are temporary and can include discomfort when urinating, urgency, inability to control the urge, pelvic pain, and some blood in the urine.4 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention.
See the UroLift System Instructions for Use for more information.
- Tubaro et al. 2003 Drugs Aging Lieber et al.
- Barry M, Roehrborn C. Management of benign prostatic hyperplasia.Annu Rev Med.1997
- Abrams, et al., Neurourology and Urodynamics 2002; Maximilian, et al., BJU Intl 2012
- Roehrborn et al. Journal of Urology 2013 LIFT Study
- Roehrborn et al. Can J Urol 2017